Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MINNEAPOLIS--(BUSINESS WIRE)--On-X® Life Technologies, Inc. (On-X LTI) announced today that enrollment for the Low-Risk Aortic Valve and Mitral Valve Patient Groups has been completed. The Prospective Randomized On-X Valve Anticoagulation Trial (PROACT) was initiated with US FDA approval in 2006 and is being conducted at 36 centers throughout the United States and Canada. The purpose of the Low-Risk Patient Group of the PROACT trial is to determine if qualified recipients of the On-X aortic heart valve can be safely maintained with aspirin and clopidogrel (Plavix®). The announcement was made today at the American Association for Thoracic Surgery (AATS) annual meeting.
Help employers find you! Check out all the jobs and post your resume.
